株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大腸癌 : パイプライン製品の分析

Colon Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229732
出版日 ページ情報 英文 672 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
大腸癌 : パイプライン製品の分析 Colon Cancer - Pipeline Review, H1 2016
出版日: 2016年06月15日 ページ情報: 英文 672 Pages
概要

大腸・結腸直腸癌は、大腸(結腸)または直腸(大腸の最終部分)に発症する癌です。単一の原因は特定できません。ほぼすべての大腸癌は、非癌性(良性)のポリープに始まり、ゆっくりと癌に進行します。多くの場合、症状はありません。腹痛や下腹部の圧痛、血便、下痢、便秘、または排便習慣の変化、原因不明の体重減少などが見られます。治療には、外科手術、放射線療法、化学療法などが含まれます。

当レポートでは、大腸癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

大腸癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7965IDB

Summary

Global Markets Direct's, 'Colon Cancer - Pipeline Review, H1 2016', provides an overview of the Colon Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colon Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Colon Cancer
  • The report reviews pipeline therapeutics for Colon Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Colon Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Colon Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Colon Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Colon Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Colon Cancer Overview
  • Therapeutics Development
  • Colon Cancer - Therapeutics under Development by Companies
  • Colon Cancer - Therapeutics under Investigation by Universities/Institutes
  • Colon Cancer - Pipeline Products Glance
  • Colon Cancer - Products under Development by Companies
  • Colon Cancer - Products under Investigation by Universities/Institutes
  • Colon Cancer - Companies Involved in Therapeutics Development
  • Colon Cancer - Therapeutics Assessment
  • Drug Profiles
  • Colon Cancer - Dormant Projects
  • Colon Cancer - Discontinued Products
  • Colon Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Colon Cancer, H1 2016
  • Number of Products under Development for Colon Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Colon Cancer - Pipeline by ACF Pharmaceuticals, LLC, H1 2016
  • Colon Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016
  • Colon Cancer - Pipeline by Aduro BioTech, Inc., H1 2016
  • Colon Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2016
  • Colon Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Colon Cancer - Pipeline by Agenus, Inc., H1 2016
  • Colon Cancer - Pipeline by AGV Discovery, SAS, H1 2016
  • Colon Cancer - Pipeline by AIMM Therapeutics B.V., H1 2016
  • Colon Cancer - Pipeline by Ambrx, Inc., H1 2016
  • Colon Cancer - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Colon Cancer - Pipeline by AndroScience Corporation, H1 2016
  • Colon Cancer - Pipeline by Aphios Corporation, H1 2016
  • Colon Cancer - Pipeline by Aposense Ltd., H1 2016
  • Colon Cancer - Pipeline by Aptose Biosciences Inc., H1 2016
  • Colon Cancer - Pipeline by Asana BioSciences, LLC, H1 2016
  • Colon Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Colon Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Colon Cancer - Pipeline by BCN Biosciences L.L.C., H1 2016
  • Colon Cancer - Pipeline by Bio-Path Holdings, Inc., H1 2016
  • Colon Cancer - Pipeline by Biogazelle, H1 2016
  • Colon Cancer - Pipeline by Bioncotech Therapeutics S.L., H1 2016
  • Colon Cancer - Pipeline by Blirt S.A., H1 2016
  • Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Colon Cancer - Pipeline by Can-Fite BioPharma Ltd., H1 2016
  • Colon Cancer - Pipeline by Celprogen, Inc., H1 2016
  • Colon Cancer - Pipeline by Celyad SA, H1 2016
  • Colon Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016
  • Colon Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Colon Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
  • Colon Cancer - Pipeline by CytomX Therapeutics, Inc., H1 2016
  • Colon Cancer - Pipeline by Cytune Pharma SAS, H1 2016
  • Colon Cancer - Pipeline by CZ BioMed Corp, H1 2016
  • Colon Cancer - Pipeline by DEKK-TEC, Inc., H1 2016
  • Colon Cancer - Pipeline by Digna Biotech, S.L., H1 2016
  • Colon Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Colon Cancer - Pipeline by EntreChem, S.L., H1 2016
  • Colon Cancer - Pipeline by EnzymeBioSystems, H1 2016
  • Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Colon Cancer - Pipeline by GlycaNova Norway AS, H1 2016
  • Colon Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2016
  • Colon Cancer - Pipeline by Heat Biologics, Inc., H1 2016
  • Colon Cancer - Pipeline by Helix BioPharma Corp., H1 2016
  • Colon Cancer - Pipeline by Histogen, Inc., H1 2016
  • Colon Cancer - Pipeline by Horizon Pharma Plc, H1 2016
  • Colon Cancer - Pipeline by Huperion Sarl, H1 2016
  • Colon Cancer - Pipeline by Idera Pharmaceuticals, Inc., H1 2016
  • Colon Cancer - Pipeline by Ignyta, Inc., H1 2016
  • Colon Cancer - Pipeline by Immunome Inc., H1 2016
  • Colon Cancer - Pipeline by Immunomedics, Inc., H1 2016
  • Colon Cancer - Pipeline by Immunotope, Inc., H1 2016
  • Colon Cancer - Pipeline by Immupharma Plc, H1 2016
  • Colon Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2016
  • Colon Cancer - Pipeline by Incuron, LLC, H1 2016
  • Colon Cancer - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
  • Colon Cancer - Pipeline by Inflection Biosciences Limited, H1 2016
  • Colon Cancer - Pipeline by Innopharmax Inc., H1 2016
  • Colon Cancer - Pipeline by Intezyne, Inc, H1 2016
  • Colon Cancer - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016
  • Colon Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016
  • Colon Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016
  • Colon Cancer - Pipeline by JW Pharmaceutical Corporation, H1 2016
  • Colon Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Colon Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Colon Cancer - Pipeline by Lipocure Ltd., H1 2016
  • Colon Cancer - Pipeline by LipoMedix Pharmaceutical Inc., H1 2016
  • Colon Cancer - Pipeline by Lupin Limited, H1 2016
  • Colon Cancer - Pipeline by Lymphocyte Activation Technologies, S.A., H1 2016
  • Colon Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016
  • Colon Cancer - Pipeline by MacroGenics, Inc., H1 2016
  • Colon Cancer - Pipeline by MaxiVAX SA, H1 2016
  • Colon Cancer - Pipeline by Meabco A/S, H1 2016
  • Colon Cancer - Pipeline by Molecular Targeting Technologies, Inc., H1 2016
  • Colon Cancer - Pipeline by MolMed S.p.A., H1 2016
  • Colon Cancer - Pipeline by Monopar Therapeutics LLC, H1 2016
  • Colon Cancer - Pipeline by Multimmune GmbH, H1 2016
  • Colon Cancer - Pipeline by NormOxys, Inc., H1 2016
  • Colon Cancer - Pipeline by Novartis AG, H1 2016
  • Colon Cancer - Pipeline by Omeros Corporation, H1 2016
  • Colon Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016
  • Colon Cancer - Pipeline by OncoVista Innovative Therapies, Inc., H1 2016
  • Colon Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Colon Cancer - Pipeline by Orega Biotech SAS, H1 2016
  • Colon Cancer - Pipeline by OSE Immunotherapeutics, H1 2016
  • Colon Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016
  • Colon Cancer - Pipeline by PharmaCyte Biotech, Inc., H1 2016
  • Colon Cancer - Pipeline by Pharminox Limited, H1 2016
  • Colon Cancer - Pipeline by Philogen S.p.A., H1 2016
  • Colon Cancer - Pipeline by Pique Therapeutics, H1 2016
  • Colon Cancer - Pipeline by Plexxikon Inc., H1 2016
  • Colon Cancer - Pipeline by Provecs Medical GmbH, H1 2016
  • Colon Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016
  • Colon Cancer - Pipeline by Qu Biologics Inc., H1 2016
  • Colon Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Colon Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016
  • Colon Cancer - Pipeline by Rgenix, Inc., H1 2016
  • Colon Cancer - Pipeline by Sareum Holdings Plc, H1 2016
  • Colon Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016
  • Colon Cancer - Pipeline by Sellas Inc., H1 2016
  • Colon Cancer - Pipeline by Sigma-Tau S.p.A., H1 2016
  • Colon Cancer - Pipeline by Sirnaomics, Inc., H1 2016
  • Colon Cancer - Pipeline by Somantix B.V., H1 2016
  • Colon Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Colon Cancer - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016
  • Colon Cancer - Pipeline by Starpharma Holdings Limited, H1 2016
  • Colon Cancer - Pipeline by Synergys Biotherapeutics, Inc., H1 2016
  • Colon Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016
  • Colon Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
  • Colon Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Colon Cancer - Pipeline by Theryte Limited, H1 2016
  • Colon Cancer - Pipeline by Transgene Biotek Limited, H1 2016
  • Colon Cancer - Pipeline by TVAX Biomedical, Inc., H1 2016
  • Colon Cancer - Pipeline by Tyg Oncology Ltd., H1 2016
  • Colon Cancer - Pipeline by Vaccinogen, Inc., H1 2016
  • Colon Cancer - Pipeline by Vault Pharma Inc., H1 2016
  • Colon Cancer - Pipeline by Vaximm AG, H1 2016
  • Colon Cancer - Pipeline by VG Life Sciences, Inc., H1 2016
  • Colon Cancer - Pipeline by Yakult Honsha Co., Ltd., H1 2016
  • Colon Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016
  • Colon Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Colon Cancer - Dormant Projects, H1 2016
  • Colon Cancer - Dormant Projects (Contd..1), H1 2016
  • Colon Cancer - Dormant Projects (Contd..2), H1 2016
  • Colon Cancer - Dormant Projects (Contd..3), H1 2016
  • Colon Cancer - Dormant Projects (Contd..4), H1 2016
  • Colon Cancer - Dormant Projects (Contd..5), H1 2016
  • Colon Cancer - Dormant Projects (Contd..6), H1 2016
  • Colon Cancer - Dormant Projects (Contd..7), H1 2016
  • Colon Cancer - Dormant Projects (Contd..8), H1 2016
  • Colon Cancer - Dormant Projects (Contd..9), H1 2016
  • Colon Cancer - Dormant Projects (Contd..10), H1 2016
  • Colon Cancer - Dormant Projects (Contd..11), H1 2016
  • Colon Cancer - Dormant Projects (Contd..12), H1 2016
  • Colon Cancer - Dormant Projects (Contd..13), H1 2016
  • Colon Cancer - Dormant Projects (Contd..14), H1 2016
  • Colon Cancer - Dormant Projects (Contd..15), H1 2016
  • Colon Cancer - Dormant Projects (Contd..16), H1 2016
  • Colon Cancer - Dormant Projects (Contd..17), H1 2016
  • Colon Cancer - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Colon Cancer, H1 2016
  • Number of Products under Development for Colon Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top